The patient with coronary stents and antiplatelet agents: What to do and how to deal?

European Journal of Anaesthesiology

Volumn 27, Issue 5, 2010, Pages 406-410

  Bornemann, Helmar ^a   Prüller, Florian ^a   Metzler, Helfried ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Coronary artery stents; Dual antiplatelet therapy; Noncardiac surgery

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; CLOPIDOGREL; CYPHER; DESMOPRESSIN; ENDEAVOR; ENOXAPARIN; EPTIFIBATIDE; PACLITAXEL; RAPAMYCIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

BLEEDING; CARDIAC PATIENT; CORONARY STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; HEART DEATH; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW; STENT THROMBOSIS; TAXUS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

ALGORITHMS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; SURGICAL PROCEDURES, OPERATIVE; THROMBOSIS;

EID: 77953776618     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e328335b284     Document Type: Review

References (44)

1. Holmes DR Jr, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53:77C-81C.
2. Farb A, Boam AB. Stent thrombosis redux: the FDA perspective. N Engl J Med 2007; 356:984-987.
3. Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices. Circulation 2007; 116:677-682. (Pubitemid 47356353)
4. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992-2000.
5. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007; 297:2001-2009.
6. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193-202.
7. Kastrati A, Schomig A. Drug-eluting stents is their future as bright as their past? J Am Coll Cardiol 2007; 50:146-148.
8. Kaul S, Shah PK, Diamond GA. As time goes by: current status and future directions in the controversy over stenting. J Am Coll Cardiol 2007; 50:128-137.
9. Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 2007; 50:109-118.
10. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008; 371:2134-2143.
11. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48:2584-2591.
12. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004; 2:535-545.
13. Metzler H, Pruller F, Munch A, et al. Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring. Eur J Anaesthesiol 2009 [Epub ahead of print].
14. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
15. Steinhubl SR, Berger PB, Mann Iii JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
16. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-1189.
17. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51:172-209.
18. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113:2803-2809.
19. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35:1288-1294.
20. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and noncardiac surgery: a prospective outcome study. Br J Anaesth 2006; 96:686-693.
21. Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 2007; 49:122-124.
22. Rabbitts JA, Nuttall GA, Brown MJ, et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 2008; 109:596-604.
23. Nuttall GA, Brown MJ, Stombaugh JW, et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 2008; 109:588-595.
24. van Kuijk JP, Flu WJ, Schouten O, et al. Timing of noncardiac surgery after coronary artery stenting with bare metal or drug-eluting stents. Am J Cardiol 2009; 104:1229-1234.
25. de Souza DG, Baum VC, Ballert NM. Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology 2007; 106:1057-1059.
26. Charbucinska KN, Godet G, Itani O, et al. Anticoagulation management for patients with drug-eluting stents undergoing vascular surgery. Anesth Analg 2006; 103:261-263.
27. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trial. Circulation 2004; 110:1202-1208.
28. Ascione R, Ghosh A, Rogers CA, et al. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 2005; 79:1210-1216.
29. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52:1693-1701.
30. Kim JH-J, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008; 156:886-892.
31. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following preoperative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2009; 53:1965-1972.
32. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005; 257:399-414.
33. Metzler H, Huber K, Kozek-Langenecker S, et al. Coronary stents, dual antiplatelet therapy and peri-operative problems. Anaesthesist 2007; 56:401-410.
34. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in noncardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Noncardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30:2769-2812.
35. Ranucci M, Nano G, Pazzaglia A, et al. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. J Cardiothorac Vasc Anesth 2007; 21:851-854.
36. Lauritzen B, Tranholm M, Ezban M. rFVIIa and a new enhanced rFVIIaanalogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats. J Thromb Haemost 2009; 7:651-657.
37. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005; 112:I-276-I-280.
38. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events poststenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005; 46:1820-1826.
39. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49:2312-2317.
40. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849-856.
41. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51:1404-1411.
42. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1822-1834.
43. May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting: a double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99:487-493.
44. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.